Last updated: September 16, 2026
Quinidine gluconate is an old, medically important antiarrhythmic with limited commercial competition and a weak modern patent barrier. The primary opportunity is not a new-molecule franchise but a reliable oral dosage form with controlled dissolution, acceptable tablet size, robust supply, and a clear FDA regulatory pathway. Excipient selection should focus on dose uniformity, moisture control, dissolution reproducibility, gastrointestinal tolerability, and compatibility with an extended-release profile.
What is the regulatory status of quinidine gluconate?
Quinidine gluconate is the gluconate salt of quinidine, a Class IA antiarrhythmic. Quinidine products have been used for atrial fibrillation, atrial flutter, and certain ventricular arrhythmias, although use has declined because of proarrhythmic risk and the availability of alternative therapies.
Historically marketed U.S. dosage forms included:
| Dosage form |
Typical strength or presentation |
Commercial status |
| Extended-release tablets |
324 mg quinidine gluconate |
Historically marketed; availability has been limited |
| Immediate-release tablets |
Various quinidine salt strengths |
Historically marketed; limited current commercial presence |
| Injectable quinidine gluconate |
Parenteral solution |
Historically used in hospital settings; supply has been constrained |
FDA labeling identifies serious risks, including QT prolongation, torsades de pointes, syncope, thrombocytopenia, cinchonism, and drug interactions. Any commercial formulation must preserve the reference product’s pharmacokinetic and cardiac-safety profile. (FDA, 2011)
Quinidine gluconate should not be confused with quinine sulfate or quinine hydrochloride. Quinine is an antimalarial and is marketed under different regulatory and clinical frameworks. Quinidine is primarily an antiarrhythmic active pharmaceutical ingredient.
What excipients are strategically important for quinidine gluconate tablets?
The strongest excipient strategy is a conventional, low-complexity oral formulation that controls tablet manufacturability without changing quinidine exposure.
Immediate-release formulation
An immediate-release quinidine gluconate tablet could use a conventional matrix comprising:
- Microcrystalline cellulose as a diluent and compression aid
- Pregelatinized starch or low-substituted hydroxypropyl cellulose as a disintegrant
- Crospovidone or croscarmellose sodium to promote tablet breakup
- Povidone or hydroxypropyl cellulose as a binder
- Colloidal silicon dioxide as a glidant
- Magnesium stearate or sodium stearyl fumarate as a lubricant
- Film-coating polymers such as hypromellose and polyethylene glycol
The formulation objective is rapid and consistent disintegration without excessive dose dumping. Quinidine gluconate is administered at clinically meaningful doses, so tablet weight and size are commercial constraints. Excessive excipient loading can produce an oversized tablet, while aggressive disintegrant levels can impair mechanical strength.
Extended-release formulation
The more commercially relevant opportunity is an extended-release tablet equivalent to the historical 324 mg product. Candidate release systems include:
| Release platform |
Candidate excipients |
Commercial assessment |
| Hydrophilic matrix |
Hypromellose, hydroxypropyl cellulose |
Low-cost and scalable; dissolution control depends on polymer grade and compression |
| Insoluble matrix |
Ethylcellulose with pore-forming excipients |
Strong release control; may require more development work |
| Multiparticulate system |
Drug-loaded pellets with polymer coating |
More flexible release profile; higher manufacturing complexity |
| Osmotic system |
Semipermeable membrane and osmotic excipients |
Technically robust but commercially difficult for a low-volume product |
| Film-coated matrix tablet |
Matrix former plus protective coat |
Practical option for a generic or 505(b)(2) product |
A hydrophilic hypromellose matrix is likely the most commercially proportionate approach. It avoids the cost and manufacturing complexity of an osmotic system while allowing adjustment of quinidine release through polymer viscosity, concentration, particle size, compression force, and coating weight.
The principal technical risk is dose dumping. Alcohol-induced release acceleration, excessive tablet porosity, and variability in polymer hydration can produce an unsafe exposure profile for a drug with a narrow therapeutic margin and proarrhythmic potential.
What excipient compatibility risks affect quinidine gluconate?
Quinidine gluconate requires a compatibility program covering chemical stability, physical stability, dissolution, and assay uniformity.
Moisture sensitivity
Hygroscopic excipients may alter tablet hardness, disintegration, and dissolution during storage. Sorbitol, certain grades of polyethylene glycol, and highly hygroscopic starch systems require careful evaluation. Low-moisture microcrystalline cellulose and controlled-humidity processing may offer a more stable platform.
Lubricant sensitivity
Magnesium stearate can reduce wettability and slow dissolution when overmixed or used at excessive concentration. This is important for both immediate-release and matrix tablets. Lubrication time should be a controlled process parameter.
Maillard and oxidative reactions
Lactose should be evaluated cautiously because reducing sugars can react with amine-containing drug substances or related impurities. A lactose-free platform using microcrystalline cellulose, mannitol, or dibasic calcium phosphate can reduce this risk, subject to dissolution and compressibility results.
pH and microenvironment effects
Quinidine is a basic compound. Excipients that create a strongly acidic or alkaline microenvironment may alter solubility, dissolution, and absorption. Buffering agents should not be added without a demonstrated biopharmaceutical benefit.
Colorants and light protection
A light-protective film coat may improve product robustness if quinidine or the formulation shows photodegradation. Colorants should be selected for regulatory acceptability and batch-to-batch consistency, particularly if the product is intended for a small market where supplier changes can create disproportionate regulatory burden.
What formulations are protected by quinidine gluconate patents?
Quinidine gluconate is an old active pharmaceutical ingredient, and the foundational composition-of-matter patent estate is expected to be expired. No meaningful current exclusivity should be assumed for the molecule itself.
Potentially relevant rights could still arise from:
- Specific extended-release matrices
- Multiparticulate delivery systems
- Abuse-deterrent or modified-release coatings
- Combination products
- Narrow method-of-use claims
- Manufacturing processes for a particular solid form
- Stability-enhancing excipient systems
These rights would need to be evaluated claim by claim. A formulation patent cannot block a product unless the commercial product practices the asserted claims. For a conventional quinidine gluconate tablet using standard excipients, the principal legal risk is likely to arise from any still-active modified-release or manufacturing patent rather than from the quinidine molecule.
The FDA Orange Book should be reviewed for listed patents associated with any current reference product before an ANDA strategy is selected. (FDA, 2024a) Historical products and discontinued products may not provide a clean, currently marketable reference-product pathway.
When does quinidine gluconate lose exclusivity?
Quinidine gluconate has already lost practical active-ingredient exclusivity in the United States. The commercial question is product availability, not loss of basic molecule protection.
| Exclusivity category |
Quinidine gluconate position |
| New chemical entity exclusivity |
Expired or not applicable to a modern generic launch |
| Orphan-drug exclusivity |
No general current protection established |
| Pediatric exclusivity |
No current protection established |
| Foundational composition patent |
Expected to be expired |
| Formulation patent risk |
Requires product-specific review |
| Method-of-use patent risk |
Requires current Orange Book and patent-file review |
| Regulatory exclusivity |
Depends on the proposed reference product and pathway |
A sponsor should not assume that the absence of an active ingredient patent guarantees immediate generic approval. FDA approval can still be constrained by reference-product availability, discontinued product status, bioequivalence complexity, or the need to characterize an older extended-release dosage form.
Is quinidine gluconate listed in the Orange Book?
Orange Book status is product-specific and changes as applications are approved, discontinued, or removed. The relevant inquiry is whether a currently approved reference listed drug exists for the proposed dosage form and strength, and whether FDA lists patents or exclusivity for that reference.
For quinidine gluconate, the practical questions are:
- Is a current FDA-approved extended-release tablet available as the reference listed drug?
- Is the reference product actively marketed?
- Does FDA identify listed patents or regulatory exclusivity?
- Can the proposed product demonstrate bioequivalence using standard pharmacokinetic endpoints?
- Does the product require a 505(b)(2) application because an ANDA reference is unavailable or unsuitable?
FDA’s Orange Book identifies approved products, therapeutic equivalence evaluations, patent information, and exclusivity data. (FDA, 2024a) A sponsor should treat historical approval records separately from an actively marketed reference product.
What FDA regulatory pathway is available?
ANDA pathway
An ANDA is commercially attractive if FDA identifies a suitable reference listed drug and the sponsor can demonstrate pharmaceutical equivalence and bioequivalence. The formulation should match the reference in active ingredient, dosage form, strength, and route of administration.
For an extended-release product, the sponsor may need:
- Comparative pharmacokinetic studies
- Fed and fasting studies
- In vitro dissolution across multiple media and agitation conditions
- Alcohol-dose-dumping studies
- Strength-scaling justification
- Stability data
- Comparative impurity and degradation profiles
505(b)(2) pathway
A 505(b)(2) application may be appropriate if the product introduces a clinically meaningful formulation change, uses a different dosage form, or lacks a suitable ANDA reference. This pathway can support a new extended-release product, a different strength, or a reformulated product with labeling supported partly by existing FDA findings.
The 505(b)(2) route carries higher development and regulatory costs than a straightforward ANDA. It may still be commercially justified if the sponsor can solve a supply problem or improve dosing convenience in a clinically important niche.
Which companies are challenging quinidine gluconate?
The current competitive landscape is limited and may include generic manufacturers, specialty pharmaceutical companies, hospital suppliers, and compounding pharmacies rather than large branded cardiovascular companies.
Because quinidine use is narrow, competition is shaped by:
- Product availability
- Contract manufacturing capacity
- Quality-system reliability
- Ability to maintain low-volume inventory
- Hospital formulary demand
- Emergency and rare-arrhythmia use
- Wholesale distribution coverage
No active, high-profile Paragraph IV campaign should be presumed without a current patent listing and litigation search. Older quinidine products have limited relevance to present-day patent litigation unless a surviving formulation patent is tied to an approved reference product.
What generic launch risks exist?
The principal generic-entry risks are operational and regulatory.
Reference-product risk
A discontinued or intermittently marketed reference product can make development and sourcing difficult. A sponsor may need to obtain multiple batches, establish product comparability, or use a 505(b)(2) strategy.
Bioequivalence risk
Modified-release products can fail because of food effects, incomplete release matching, or differences in terminal exposure. The cardiac safety profile increases the importance of avoiding unexpectedly high concentrations.
Manufacturing risk
Low annual volume can make specialized equipment and validated cleaning procedures uneconomic. A conventional matrix tablet is more attractive because it can be produced using standard high-shear granulation, roller compaction, or direct compression equipment.
Supply-chain risk
Quinidine gluconate API may have limited qualified suppliers. Dual sourcing, impurity controls, and an established change-control strategy are important because a small product may not support frequent process changes.
What commercial opportunities exist for quinidine gluconate?
The opportunity is a specialty generic or hospital-focused product rather than a mass-market cardiovascular product.
Hospital and specialty distribution
A reliable extended-release tablet could serve hospitals, electrophysiology centers, specialty pharmacies, and patients maintained on legacy quinidine therapy. Commercial success would depend on continuity of supply and predictable wholesaler availability.
Reformulation opportunity
A sponsor could differentiate through:
- Smaller tablets
- Improved swallowability
- Lower tablet burden
- More robust moisture stability
- Packaging optimized for low-volume distribution
- A carefully controlled extended-release profile
- A 505(b)(2) product with updated labeling or dosing flexibility
Geographic expansion
The United States is the most regulated opportunity, but quinidine remains relevant in selected international markets for arrhythmias and certain rare indications. Geographic expansion would require country-specific review of approved indications, pharmacopoeial standards, serialization, and pharmacovigilance obligations.
Revenue exposure
Revenue potential is constrained by the narrow indication, low prescribing volume, generic pricing pressure, and competition from other antiarrhythmics. The product may nevertheless have strategic value if it occupies a supply-constrained niche with limited active competitors. Hospital contracting and shortage-period pricing can materially affect returns, but revenue forecasts require current prescription, tender, and supply data.
How strong is the quinidine gluconate patent estate?
The patent estate is weak for the active ingredient and potentially moderate only for narrowly claimed delivery systems.
| Patent layer |
Relative strength |
| Quinidine molecule |
Very weak; legacy protection expected to be expired |
| Quinidine gluconate salt |
Weak unless a specific later claim remains active |
| Conventional immediate-release tablet |
Weak |
| Extended-release matrix |
Product-specific; potentially moderate |
| Multiparticulate or osmotic delivery |
Potentially stronger if claims remain active |
| Manufacturing process |
Variable and jurisdiction-specific |
| Method of use |
Limited unless linked to a current approved indication and listed patent |
Patent clearance should focus on any active claims covering the exact extended-release architecture, coating composition, pellet structure, or manufacturing process. A basic cellulose-based matrix using standard excipients is less likely to create material freedom-to-operate risk than a proprietary multiparticulate or osmotic system.
What litigation and settlement issues affect quinidine gluconate?
No current major Paragraph IV litigation or settlement should be assumed without a current review of FDA patent listings, federal court dockets, and ANDA litigation records. The historical age of quinidine gluconate makes large-scale patent litigation less likely than in newer cardiovascular products.
The principal legal workstreams are:
- Orange Book patent verification
- Paragraph IV certification analysis
- Freedom-to-operate review for modified-release technology
- Patent-term and terminal-disclaimer review
- Product-by-process claim analysis
- State substitution and therapeutic-equivalence review
- Manufacturing know-how and trade-secret diligence
Key Takeaways
- Quinidine gluconate has little apparent active-ingredient patent value; commercial protection is more likely to arise from formulation execution and supply reliability.
- A hydrophilic extended-release matrix is the most practical excipient platform for a commercial tablet.
- Excipients should be selected to control dose uniformity, moisture, dissolution, lubricant effects, and alcohol-induced dose dumping.
- The primary FDA risk is identifying a suitable current reference product, not overcoming an old composition patent.
- An ANDA is preferable when a qualifying reference listed drug is available; a 505(b)(2) application may be needed for a novel or reformulated product.
- The commercial opportunity is a specialty, hospital-oriented product with limited but potentially defensible demand.
- No current Paragraph IV litigation or settlement should be presumed without product-specific patent and docket verification.
- The strongest differentiation would come from reliable availability, a robust extended-release profile, and manufacturing simplicity.
FAQs
Is quinidine gluconate the same as quinine?
No. Quinidine is an antiarrhythmic; quinine is primarily an antimalarial. Their salts, labels, clinical uses, and regulatory histories differ.
Can quinidine gluconate be formulated with lactose?
Lactose may be technically feasible, but compatibility testing is required because reducing sugars can create stability concerns with amine-containing drug substances. A lactose-free platform may reduce formulation risk.
Is an extended-release quinidine gluconate tablet commercially attractive?
It can be attractive as a specialty generic if the sponsor can secure API supply, establish bioequivalence, and maintain reliable distribution. The market is too narrow for a high-cost delivery platform unless it creates a clear regulatory or clinical advantage.
What excipient is most important for extended-release quinidine gluconate?
Hypromellose is a practical starting point for a hydrophilic matrix because its viscosity and concentration can be adjusted to control release. The final choice must be based on dissolution, stability, and pharmacokinetic performance.
Does quinidine gluconate have biosimilar risk?
No. Quinidine gluconate is a small-molecule drug, so the relevant competition is generic or 505(b)(2) competition, not biosimilars.
References
- U.S. Food and Drug Administration. (2011). Quinidine gluconate extended-release tablets prescribing information.
- U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024b). Inactive ingredient database.
- United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
- U.S. Code of Federal Regulations. (2024). 21 C.F.R. Parts 210, 211, 314, and 320.
